Cargando…
Safety and efficacy of non–vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation
BACKGROUND: In trials of patients with atrial fibrillation (AF), non–vitamin K antagonist oral anticoagulants (NOACs) were not inferior to warfarin for thromboembolic and bleeding events. However, there are scant data comparing the efficacy and safety of NOACs in patients with AF with that of well-c...
Autores principales: | Yamkasikorn, Janekij, Methavigul, Komsing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321168/ https://www.ncbi.nlm.nih.gov/pubmed/37551377 http://dx.doi.org/10.2478/abm-2022-0016 |
Ejemplares similares
-
Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT(2)R(2) score
por: Methavigul, Komsing, et al.
Publicado: (2023) -
Use of simplified HAS‐BLED score in patients with atrial fibrillation receiving warfarin
por: Methavigul, Komsing, et al.
Publicado: (2019) -
Revised HAS‐BLED score for bleeding prediction in atrial fibrillation patients with oral anticoagulants
por: Methavigul, Komsing
Publicado: (2022) -
Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
por: Luengsupabul, Sirote, et al.
Publicado: (2020) -
Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)